Amendment December 9, 2022: Article updated to include research on mycophenolate mofetil discontinuation and COVID-19 vaccine response (see section "Do patients need to stop or alter RMD drug treatments when having a COVID-19 vaccine?").
Amendment August 30, 2022: Article updated to include study results on the effectiveness and safety of vaccination in young people (see section "Should children and adolescents with RMDs receive a COVID-19 vaccine?"), and a study on how COVID-19 outcomes differ over time with the introduction of vaccines and other factors (see section "Will COVID-19 vaccines work in people with RMDs and how can effectiveness be measured?").
Amendment June 30, 2022: Article updated to include the VROOM trial of temporary methotrexate suspension after receipt of a COVID-19 booster vaccine (see section "Do patients need to stop or alter RMD drug treatments when having a COVID-19 vaccine?").
Amendment June 9, 2022: Article updated to include findings from the MIVAC I and MIVAC II studies on when may be best to pause methotrexate treatment (see section "Do patients need to stop or alter RMD drug treatments when having a COVID-19 vaccine?").
Amendment May 12, 2022: Article updated to include studies on predictors of flare risk (see section "Is there a risk for disease flare or other adverse events with COVID-19 vaccination?") and breakthrough infection risk (see section "Will COVID-19 vaccines work in people with RMDs and how can effectiveness be measured?"), as well as the impact of immunomodulatory therapy regimens on vaccine response (see section "Do patients need to stop or alter RMD drug treatments when having a COVID-19 vaccine?").
Amendment March 8, 2022: Article updated to include a randomized controlled trial evaluating the impact of methotrexate withdrawal on vaccine immunogenicity (see section "Do patients need to stop or alter RMD drug treatments when having a COVID-19 vaccine?").
Amendment February 22, 2022: Article updated to include a study on the safety and immunogenicity of COVID-19 vaccines in adolescents with rheumatic diseases (see section "Should children and adolescents with RMDs receive a COVID-19 vaccine?").
Amendment February 14, 2022: Article updated to include:
- research on the durability and predictors of antibody response following vaccination (see section "Will COVID-19 vaccines work in people with RMDs and how can effectiveness be measured?);
- a meta-analysis of vaccine responses in patients treated with anti-CD20 therapies (see section "What are the considerations with rituximab?"); and
- a link to EULAR guidance on answering patients' questions about COVID-19 vaccination (see section: "What resources are available on COVID-19 vaccination in RMD patients?").
Amendment January 20, 2022: Article updated to include the results of two studies on antibody responses following a third vaccine dose in people on rituximab (see section "What are the considerations with rituximab?").
Amendment January 10, 2022: Article updated to include three studies on factors associated with vaccine response in rituximab-treated patients (see section "What are the considerations with rituximab?").
Amendment November 30, 2021: Article updated to include research on B-cell counts and booster vaccine response (see section "What are the considerations with rituximab?") and a study of breakthrough COVID-19 outcomes in fully and partially vaccinated people (see section "Will COVID-19 vaccines work in people with RMDs and how can effectiveness be measured?").
Amendment November 3, 2021: Article updated to include study results on flare risk following vaccination in people with rheumatoid arthritis and safety findings in patients with antiphospholipid antibodies (see section "Is there a risk for disease flare or other adverse events with COVID-19 vaccination?"), as well as findings on vaccine immunogenicity in patients with giant cell arteritis and myopathy and the impact of booster doses in those with rheumatoid arthritis (see section "Will COVID-19 vaccines work in people with RMDs and how can effectiveness be measured?").
Amendment October 13, 2021: Article updated to include a study on humoral response to COVID-19 vaccination in patients taking JAK inhibitors (see section "Do patients need to stop or alter RMD drug treatments when having a COVID-19 vaccine?").
Amendment October 8, 2021: Article updated with a study on vaccine effectiveness against emerging variants in patients with lupus.
Amendment September 16, 2021: Article updated to include research on rates of breakthrough COVID-19 following vaccination and booster doses in people with autoimmune diseases (see section "Will COVID-19 vaccines work in people with RMDs and how can effectiveness be measured?), as well as data from the COVID-19 Global Rheumatology Alliance on patient experience of vaccination (see section: "Are there any issues with vaccine uptake in RMD patients and how can we improve uptake?).
Amendment September 13, 2021: Article updated to include a study identifying predictors of response to vaccination in rituximab-treated patients, early research comparing different vaccine types, and a safety evaluation of mRNA vaccines in adolescent patients.
Amendment September 8, 2021: Article updated to include a systematic review and meta-analysis evaluating the antibody response to mRNA vaccines in people with inflammatory diseases.
Amendment August 17, 2021: Article updated to include US regulatory authorization of a third vaccine dose in certain RMD patients, and research on vaccine effectiveness in those with lupus.
Amendment August 11, 2021: Article updated to include research on flare risk following vaccination and two studies on vaccine immunogenicity.
Amendment August 2, 2021: Article updated to include a phase 4 study evaluating immunogenicity of an inactivated vaccine.
Amendment July 14, 2021: Article updated to include study results on methotrexate treatment and vaccine immunogenicity.
Amendment June 25, 2021: Article updated to include a study showing the importance of the second vaccine dose in patients with rheumatoid arthritis (RA).
Amendment June 23, 2021: Article updated to include the results of two studies covering COVID-19 vaccine immunogenicity and tolerability.
Amendment June 8, 2021: Article updated to include data on COVID-19 vaccination presented at the EULAR 2021 Virtual Congress.
Amendment May 26, 2021: Article updated to include the results of a study on methotrexate and the immune response to vaccination, a case series describing the characteristics of vaccine nonresponders, and a link to guidance from the Canadian Rheumatology Association.
Amendment May 19, 2021: Article updated to include information on COVID-19 vaccination in children and adolescents with rheumatic diseases.
Amendment May 11, 2021: Article updated to include research demonstrating impaired antibody responses to COVID-19 vaccination in people with inflammatory diseases, and the results of a small study evaluating humoral and cell-mediated responses in people undergoing rituximab treatment.
Amendment March 31, 2021: Article updated to include study results that demonstrate immunogenicity of messenger (m)RNA vaccines against SARS-CoV-2 in people with chronic inflammatory diseases, and provide information on local and systemic adverse events following vaccination.